(June 29, 2021, 1:00 PM EDT) -- SEATTLE — Two shareholders of a pharmaceutical company that develops certain treatments for neurological diseases sued the company and its CEO in Washington federal court on June 25, alleging that the company’s use of doctoral research that had previously been conducted by the CEO in developing their treatments was tainted by the CEO’s “scientific misconduct” and that, as a result, the company’s positive statements regarding its business and financial condition were false and misleading pursuant to federal securities law....